Oppenheimer initiated coverage of Inari Medical (NARI) with an Outperform rating and $75 price target Inari is a leader in the thrombectomy for the treatment of deep vein thrombosis and pulmonary embolism, notes the analyst, who says “competition is tough,” but adds that the market is still underpenetrated in the U.S. Ongoing clinical trials provide potential acceleration ahead while Inari also has a number of new opportunities beyond DVT/PE that the firm believes can drive “solid revenue growth and multiple expansion,” the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical enters joint venture with 6 Dimensions Capital
- Inari Medical reports PEERLESS study met primary composite endpoint
- Inari Medical price target raised to $50 from $46 at Truist
- Inari Medical price target raised to $74 from $71 at Canaccord
- Inari Medical price target raised to $67 from $66 at Baird